KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.

Ye-Lin Liang, Xu Liu, Liang-Fang Shen, Guang-Yuan Hu, Guo-Rong Zou, Ning Zhang, Chuan-Ben Chen, Xiao-Zhong Chen, Xiao-Dong Zhu, Ya-Wei Yuan, Kun-Yu Yang, Feng Jin, Wei-Han Hu, Fang-Yun Xie, Ying Huang, Fei Han, Ling-Long Tang, Yan-Ping Mao, Li-Xia Lu, Rui Sun, Yu-Xiang He, Yang-Ying Zhou, Guo-Xian Long, Jie Tang, Lu-Si Chen, Jing-Feng Zong, Ting Jin, Ling Li, Jie Lin, Jing Huang, Xiu-Yun Gong, Guan-Qun Zhou, Lei Chen, Wen-Fei Li, Yu-Pei Chen, Cheng Xu, Li Lin, Shao-Hui Huang, Sai-Wei Huang, Ya-Qin Wang, Cheng-Long Huang, Hui-Xia Feng, Min Hou, Chun-Hua Chen, Su-Fen Zheng, Ying-Qing Li, Shu-Bin Hong, Yu-Sheng Jie, Hao Li, Jing-Ping Yun, Sheng-Bing Zang, Song-Ran Liu, Qing-Guang Lin, Hao-Jiang Li, Li Tian, Li-Zhi Liu, Hong-Yun Zhao, Ji-Bin Li, Ai-Hua Lin, Na Liu, Yuan Zhang, Rui Guo, Jun Ma, Ying Sun

JAMA 333(18) 1589-1598

PMID40079940
PMCIDPMC11907361
DOI10.1001/jama.2025.1132
发表日期2025-03-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

IMPORTANCE: Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role in locoregionally advanced NPC is unclear. OBJECTIVE: To evaluate the efficacy and safety of adjuvant camrelizumab for patients with locoregionally advanced NPC. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, multicenter, phase 3 clinical trial conducted from August 2018 to November 2021 at 11 centers in China and enrolling 450 patients with T4N1M0 or T1-4N2-3M0 NPC who had completed induction-concurrent chemoradiotherapy. The final date of follow-up was March 20, 2024. INTERVENTIONS: Patients were randomized (1:1) to receive adjuvant camrelizumab (200 mg intravenously once every 3 weeks for 12 cycles; n = 226) or observation (standard therapy group; n = 224). MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival (freedom from distant metastasis, locoregional relapse, or death due to any cause). Secondary end points included distant metastasis-free survival, locoregional relapse-free survival, overall survival, safety, and health-related quality of life. RESULTS: Among the 450 participants (mean age, 45 [SD, 10] years; 24% women), after a median follow-up of 39 (IQR, 33-50) months, the camrelizumab group had a 3-year event-free survival rate of 86.9%, whereas the standard therapy group had a rate of 77.3% (stratified hazard ratio, 0.56; 95% CI, 0.36-0.89; P = .01). Grade 3 or 4 adverse events were reported in 23 patients (11.2%) in the camrelizumab and 7 (3.2%) in the standard therapy group. Reactive capillary endothelial proliferation was the most common adverse event related to camrelizumab, occurring in 85.8% of patients at grade 1 or 2, while 2% of patients had grade 3 or 4 events. There was no significant deterioration in quality of life associated with camrelizumab treatment. CONCLUSIONS AND RELEVANCE: Adjuvant PD-1 blockade with camrelizumab significantly improved event-free survival with manageable toxicities, highlighting its potential role in the management of locoregionally advanced NPC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03427827.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。